New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:47 EDTCG, JNJJNJ accepts $4B binding offer from Carlyle to acquire Ortho-Clinical Diagnostics
Johnson & Johnson (JNJ) announced that it has accepted the binding offer from Carlyle Group (CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions. :theflyonthe
News For JNJ;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
08:26 EDTCGCarlyle Group management to meet with Sandler O'Neill
Subscribe for More Information
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
16:24 EDTCGBlackstone, Carlyle, KKR potential buyers of Armacell, Reuters says
Britain's Charterhouse has established a Friday deadline for bids on its insulation materials company Armacell, which may be valued at up to $1.06B, reports Reuters, citing sources. The business has attracted interest from private equity firms, with Blackstone (BX), Carlyle (CG), and KKR (KKR) "cited as potential buyers," according to the report. Reference Link
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 17, 2015
11:35 EDTCGFinancing backing Carlyle's purchase of Symantec's Veritas pulled, Reuters says
Subscribe for More Information
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information
November 12, 2015
10:05 EDTCGHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use